Maze Therapeutics (NASDAQ:MAZE) Earns Buy Rating from HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 317.09% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Wedbush reiterated an “outperform” rating and issued a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday. Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday. They set a “buy” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Trading Down 6.1%

Shares of Maze Therapeutics stock traded down $1.72 on Thursday, reaching $26.37. The company had a trading volume of 429,914 shares, compared to its average volume of 660,514. The firm’s 50 day moving average price is $27.18 and its two-hundred day moving average price is $29.17. The firm has a market cap of $1.46 billion, a PE ratio of -10.49 and a beta of 2.17. Maze Therapeutics has a 52-week low of $21.95 and a 52-week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). Sell-side analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Activity at Maze Therapeutics

In related news, CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the sale, the insider directly owned 26,250 shares of the company’s stock, valued at $717,675. This trade represents a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 191,459 shares of company stock worth $5,263,539. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MAZE. TRV GP IV LLC acquired a new position in Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics in the 2nd quarter valued at about $122,983,582. BlackRock Inc. bought a new stake in Maze Therapeutics in the 2nd quarter valued at about $104,525,000. Jupiter Topco LLC bought a new stake in Maze Therapeutics in the 2nd quarter valued at about $101,764,000. Finally, Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the second quarter valued at about $41,435,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.